EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524

Sally J Coggins iD, Jacqui M Norris, Richard Malik, Merran Govendir, Evelyn J Hall, Benjamin Kimble, Mary F Thompson

Journal of Veterinary Internal Medicine · 2023

DOI: 10.1111/jvim.16803 ↗

At a glance

Journal article in Journal of Veterinary Internal Medicine, 2023. Written by Sally J Coggins and 6 co-authors. Institution: Sydney School of Veterinary Science, The University of Sydney, Sydney, New South Wales, Australia. Major MEDLINE topics: Feline Infectious Peritonitis, Coronavirus, Feline, Cat Diseases. Cited 73 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Cat Protection Society of NSW, EveryCat Health Foundation, Open access publishing facilitated by The University of Sydney, as part of the Wiley - The University of Sydney agreement via the Council of Australian Univers….

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Nucleoside analog GS-441524 is effective in treating cats with feline infectious peritonitis (FIP). Investigation into the use of parent nucleotide analog remdesivir (GS-5734) is needed.

Objectives

To assess efficacy and tolerability of remdesivir with or without transition to GS-441524 in cats with FIP and document clinical and clinicopathologic progression over 6 months. Animals Twenty-eight client-owned cats with FIP.

Methods

Cats were prospectively recruited between May 2021 and May 2022. An induction dosage of remdesivir 10 to 15 mg/kg intravenously or subcutaneously q24h was utilized for 4 doses, with a maintenance dosage of remdesivir (6-15 mg/kg SC) or GS-441524 (10-15 mg/kg per os) every 24 hours continued for at least 84 days. Laboratory testing, veterinary, and owner assessments were recorded.

Results

Twenty-four cats survived to 6 months (86%). Three cats died within 48 hours. Excluding these, survival from 48 hours to 6 months was 96% (24/25). Remission was achieved by day 84 in 56% (14/25). Three cats required secondary treatment for re-emergent FIP. Remission was achieved in all 3 after higher dosing (15-20 mg/kg). Adverse reactions were occasional site discomfort and skin irritation with remdesivir injection. Markers of treatment success included resolution of pyrexia, effusions, and presenting signs of FIP in the first half of treatment and normalization of globulin concentration, and continued body weight gains in the latter half of the treatment period. Conclusions and Clinical Importance Parenteral administration of remdesivir and oral administration of GS-441524 are effective and well-tolerated treatments for FIP. Early emphasis on clinical, and later emphasis on clinicopathologic response, appears prudent when monitoring treatment efficacy.

Subjects

MeSH terms (MEDLINE)

Feline Infectious PeritonitisCoronavirus, FelineCat DiseasesHumansCatsAnimalsExudates and TransudatesAdenosine MonophosphateAlanineAdenosine

Author keywords

antiviralclinical trialfeline coronavirusnucleoside analog

Substances

remdesivirAdenosine MonophosphateAlanineGS-441524Adenosine

Authors and institutions

  • Sydney School of Veterinary Science, The University of Sydney, Sydney, New South Wales, Australia.
  • Centre for Veterinary Education, The University of Sydney, NSW, Australia.
  • Animal and Veterinary Science, Charles Sturt University, NSW, Australia.

ORCID profiles: Sally J Coggins

Funding

  • Cat Protection Society of NSW
  • EveryCat Health Foundation
  • Open access publishing facilitated by The University of Sydney, as part of the Wiley - The University of Sydney agreement via the Council of Australian Univers…

Cite

APA

Coggins, S. J., Norris, J. M., Malik, R., Govendir, M., Hall, E. J., Kimble, B., & Thompson, M. F. (2023). Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.16803

Vancouver

Coggins SJ, Norris JM, Malik R, Govendir M, Hall EJ, Kimble B, et al. Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524. Journal of Veterinary Internal Medicine. 2023. doi:10.1111/jvim.16803

BibTeX
@article{Coggins2023,
  author = {Coggins, Sally J and Norris, Jacqui M and Malik, Richard and Govendir, Merran and Hall, Evelyn J and Kimble, Benjamin and Thompson, Mary F},
  title = {Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2023},
  doi = {10.1111/jvim.16803}
}
Start for free →